Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. [electronic resource]
Producer: 20151204Description: 279-88 p. digitalISSN:- 1573-7217
- Antigens, Neoplasm -- genetics
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- metabolism
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- DNA Topoisomerases, Type II -- genetics
- DNA-Binding Proteins -- genetics
- Disease-Free Survival
- Female
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Multivariate Analysis
- Prognosis
- Proportional Hazards Models
- Receptor, ErbB-2 -- genetics
- Risk
- Taxoids -- administration & dosage
- Tissue Inhibitor of Metalloproteinase-1 -- metabolism
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.